Sandy, Utah-based SilverVue has received an undisclosed round of funding led by Pritzker Group Venture Capital and GE Ventures, with participation from Epic Ventures.
“Empowering patients to make more informed decisions about their medical care is more than our business, it’s our passion,” Will West, CEO and founder of SilverVue, said in a statement. “Hundreds of healthcare providers have recognized the need for educating and equipping patients with information about accessible, high quality care – and as a result – hospitals throughout the US are choosing SilverVue. Together with our premier group of healthcare investors, we are committed to improving outcomes for patients.”
SilverVue is a software company that makes a flagship product called SilverSearch, a tablet app. Hospital case managers use SilverSearch to help patients choose a post-acute care provider by serving up CMS ratings and information about PAC providers throughout the US. Patients can filter searches based on the particular specialty of care they need (including long-term acute care, inpatient rehabilitation facility, skilled nursing facility, and home health agency) and by zip code or accepted insurance plans.
SilverSearch is deployed in several hospitals, including Brookdale University Hospital Medical Center in Brooklyn, New York and North Vista Hospital in Las Vegas, Nevada.
“We’re enthusiastic with not only how SilverVue is currently serving hospitals and post-acute providers, but also how they will help patients access other technology services," Noah Lewis, Managing Partner at GE Ventures, said in a statement. "We are excited to back this team of serial entrepreneurs as they work to continually improve patient engagement and the quality of healthcare.”
SilverVue is a relatively young company, but it has already made an acquisition. In July 2015, the company completed a strategic acquisition of ProMD, makers of mobile health technology platform MobiMD. The app was designed to facilitate communications between hospitals and their post-discharge patient populations.
